33 trials changed in the last 30 days: 1 stopped, 8 with notable changes, 24 with minor changes only.
Trial terminated
Also in this update: Trial sites reduced: 16 → 10 locations; Primary completion date changed from estimate of Feb 1, 2027 to Aug 28, 2026
Bristol-Myers SquibbPhase 1 NCT06419634 Registry history of NCT06419634 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Mar 13, 2026 to Feb 16, 2027
Bristol-Myers SquibbPhase 3 NCT06140836 Registry history of NCT06140836 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Results posted: Sep 22, 2026
Bristol-Myers SquibbPhase 3 NCT04810078 Registry history of NCT04810078 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites reduced: 208 → 201 locations
Bristol-Myers SquibbPhase 3 NCT07680790 Registry history of NCT07680790 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Bristol-Myers SquibbNot specified NCT07355478 Registry history of NCT07355478 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Aug 26, 2026 to Aug 31, 2026
Bristol-Myers SquibbPhase 1 NCT07800897 Registry history of NCT07800897 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Bristol-Myers SquibbPhase 1 NCT07763418 Registry history of NCT07763418 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 1 → 6 locations
Bristol-Myers SquibbPhase 1 NCT07780383 Registry history of NCT07780383 on ClinicalTrials.gov (opens the registry)
Results posted: Oct 14, 2026
Bristol-Myers SquibbPhase 1/2 NCT05337137 Registry history of NCT05337137 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Sep 5, 2024 to Oct 10, 2024
Bristol-Myers SquibbPhase 3 NCT04908202 Registry history of NCT04908202 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of May 26, 2027 to Sep 9, 2026
Bristol-Myers SquibbPhase 1 NCT06799286 Registry history of NCT06799286 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Final enrollment: 69 participants (planned 24)
Bristol-Myers SquibbPhase 1 NCT07248839 Registry history of NCT07248839 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Mar 31, 2026 to Feb 28, 2026
Bristol-Myers SquibbNot specified NCT07458542 Registry history of NCT07458542 on ClinicalTrials.gov (opens the registry)
Trial completed
Bristol-Myers SquibbNot specified NCT07571148 Registry history of NCT07571148 on ClinicalTrials.gov (opens the registry)
Trial completed
Bristol-Myers SquibbNot specified NCT06971185 Registry history of NCT06971185 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jul 18, 2026 to Sep 28, 2026
Also in this update: Trial sites reduced: 207 → 204 locations
Bristol-Myers SquibbPhase 3 NCT05552976 Registry history of NCT05552976 on ClinicalTrials.gov (opens the registry)
Enrollment reduced: 225 → 180 participants
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyPhase 4 NCT07681076 Registry history of NCT07681076 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 31, 2026 to Nov 2, 2026
Bristol-Myers SquibbPhase 1 NCT07544628 Registry history of NCT07544628 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 13 → 16 locations
Bristol-Myers SquibbPhase 4 NCT07221877 Registry history of NCT07221877 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 154 → 157 locations
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyPhase 3 NCT06126224 Registry history of NCT06126224 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 94 → 104 locations
And 2 more changes in the last 30 days
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyPhase 3 NCT07424404 Registry history of NCT07424404 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 408 → 411 locations
And 1 more change in the last 30 days
Bristol-Myers SquibbPhase 3 NCT07116967 Registry history of NCT07116967 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 212 → 227 locations
CelgenePhase 3 NCT06764485 Registry history of NCT06764485 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 279 → 284 locations
Bristol-Myers SquibbPhase 3 NCT07361510 Registry history of NCT07361510 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 63 → 67 locations
Bristol-Myers SquibbPhase 3 NCT07285798 Registry history of NCT07285798 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 293 → 296 locations
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyPhase 3 NCT06585787 Registry history of NCT06585787 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 55 → 58 locations
CelgenePhase 2 NCT06782490 Registry history of NCT06782490 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Sep 5, 2031 to Jul 14, 2031
Also in this update: Primary completion moved earlier from Apr 6, 2028 to Aug 17, 2027
Bristol-Myers SquibbPhase 3 NCT06646276 Registry history of NCT06646276 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Jan 30, 2027 to Aug 11, 2026
Bristol-Myers SquibbPhase 1/2 NCT06035497 Registry history of NCT06035497 on ClinicalTrials.gov (opens the registry)
Interventions modified
Also in this update: Start date changed from estimate of Aug 31, 2026 to Sep 10, 2026
Bristol-Myers SquibbPhase 2 NCT07680764 Registry history of NCT07680764 on ClinicalTrials.gov (opens the registry)
Study completion pushed from May 31, 2026 to Nov 27, 2026
Bristol-Myers SquibbNot specified NCT07465029 Registry history of NCT07465029 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jun 30, 2026 to Dec 31, 2026
Bristol-Myers SquibbNot specified NCT06372457 Registry history of NCT06372457 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Dec 31, 2025 to Dec 31, 2027
Bristol-Myers SquibbNot specified NCT07107373 Registry history of NCT07107373 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-14 | NCT07873931 A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases | Phase 1 | Not Yet Recruiting |
| 2026-10-13 | NCT07871214 A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered… | Phase 2 | Not Yet Recruiting |
| 2026-10-01 | NCT07852884 First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain | Active, Not Recruiting | |
| 2026-10-01 | NCT07852962 Study to Assess Drug Levels, Immune Response, Safety and Tolerability of BMS-986446 in… | Phase 1 | Not Yet Recruiting |
| 2026-09-30 | NCT07848295 A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear… | Phase 1 | Not Yet Recruiting |
| 2026-09-29 | NCT07846059 Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic… | Not Yet Recruiting | |
| 2026-09-23 | NCT07837115 A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess… | Phase 1 | Not Yet Recruiting |
| Phase 1 | 34 | |
| Phase 1/2 | 23 | |
| Phase 2 | 24 | |
| Phase 2/3 | 11 | |
| Phase 3 | 66 | |
| Phase 4 | 8 |
Lung Cancer (31) · Non-Small Cell Lung Cancer (NSCLC) (29) · Multiple Myeloma (18) · Psoriasis (17) · Heart Disease (14) · Alzheimer's Disease (13) · Dementia (13) · Non-Hodgkin Lymphoma (13) · Lupus (SLE) (10) · Leukemia (9)